共查询到20条相似文献，搜索用时 15 毫秒
1.
The concept of adaptive two‐stage designs is applied to the problem of testing the equality of several normal means against an ordered (monotone) alternative. The likelihood‐ratio‐test proposed by Bartholomew is known to have favorable power properties when testing against a monotonic trend. Tests based on contrasts provide a flexible way to incorporate available information regarding the pattern of the unknown true means through appropriate specification of the scores. The basic idea of the presented concept is the combination of Bartholomew 's test (first stage) with an “adaptive score test” (second stage) which utilizes the information resulting from isotonic regression estimation at the first stage. In a Monte Carlo simulation study the adaptive scoring procedure is compared to the non‐adaptive two‐stage procedure using the Bartholomew test at both stages. We found that adaptive scoring may improve the power of the two stage design, in particular if the sample size at the first stage is considerably larger than at the second stage. 相似文献
2.
Gerhard Hommel 《Biometrical journal. Biometrische Zeitschrift》2001,43(5):581-589
It is investigated how one can modify hypotheses in a trial after an interim analysis such that the type I error rate is controlled. If only a global statement is desired, a solution was given by Bauer (1989). For a general multiple testing problem, Kieser , Bauer and Lehmacher (1999) and Bauer and Kieser (1999) gave solutions, by means of which the initial set of hypotheses can be reduced after the interim analysis. The same techniques can be applied to obtain more flexible strategies, as changing weights of hypotheses, changing an a priori order, or even including new hypotheses. It is emphasized that the application of these methods requires very careful planning of a trial as well as a critical discussion of the scientific aims in order to avoid every manipulation. 相似文献
3.
Summary Phase II trials in oncology are usually conducted as single-arm two-stage designs with binary endpoints. Currently available adaptive design methods are tailored to comparative studies with continuous test statistics. Direct transfer of these methods to discrete test statistics results in conservative procedures and, therefore, in a loss in power. We propose a method based on the conditional error function principle that directly accounts for the discreteness of the outcome. It is shown how application of the method can be used to construct new phase II designs that are more efficient as compared to currently applied designs and that allow flexible mid-course design modifications. The proposed method is illustrated with a variety of frequently used phase II designs. 相似文献
4.
Inference after two‐stage single‐arm designs with binary endpoint is challenging due to the nonunique ordering of the sampling space in multistage designs. We illustrate the problem of specifying test‐compatible confidence intervals for designs with nonconstant second‐stage sample size and present two approaches that guarantee confidence intervals consistent with the test decision. Firstly, we extend the well‐known Clopper–Pearson approach of inverting a family of two‐sided hypothesis tests from the group‐sequential case to designs with fully adaptive sample size. Test compatibility is achieved by using a sample space ordering that is derived from a test‐compatible estimator. The resulting confidence intervals tend to be conservative but assure the nominal coverage probability. In order to assess the possibility of further improving these confidence intervals, we pursue a direct optimization approach minimizing the mean width of the confidence intervals. While the latter approach produces more stable coverage probabilities, it is also slightly anti‐conservative and yields only negligible improvements in mean width. We conclude that the Clopper–Pearson‐type confidence intervals based on a test‐compatible estimator are the best choice if the nominal coverage probability is not to be undershot and compatibility of test decision and confidence interval is to be preserved. 相似文献
5.
Consider a population in which the variable of interest tends to be at or near zero for many of the population units but a subgroup exhibits values distinctly different from zero. Such a population can be described as rare in the sense that the proportion of elements having nonzero values is very small. Obtaining an estimate of a population parameter such as the mean or total that is nonzero is difficult under classical fixed sample-size designs since there is a reasonable probability that a fixed sample size will yield all zeroes. We consider inverse sampling designs that use stopping rules based on the number of rare units observed in the sample. We look at two stopping rules in detail and derive unbiased estimators of the population total. The estimators do not rely on knowing what proportion of the population exhibit the rare trait but instead use an estimated value. Hence, the estimators are similar to those developed for poststratification sampling designs. We also incorporate adaptive cluster sampling into the sampling design to allow for the case where the rare elements tend to cluster within the population in some manner. The formulas for the variances of the estimators do not allow direct analytic comparison of the efficiency of the various designs and stopping rules, so we provide the results of a small simulation study to obtain some insight into the differences among the stopping rules and sampling approaches. The results indicate that a modified stopping rule that incorporates an adaptive sampling component and utilizes an initial random sample of fixed size is the best in the sense of having the smallest variance. 相似文献
6.
Aiyi Liu James F. Troendle Kai F. Yu Vivian W. Yuan 《Biometrical journal. Biometrische Zeitschrift》2004,46(6):760-768
We consider estimation after a group sequential test. An estimator that is unbiased or has small bias may have substantial conditional bias (Troendle and Yu, 1999, Coburger and Wassmer, 2001). In this paper we derive the conditional maximum likelihood estimators of both the primary parameter and a secondary parameter, and investigate their properties within a conditional inference framework. The method applies to both the usual and adaptive group sequential test designs. (© 2004 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim) 相似文献
7.
This article deals with sample size reassessment for adaptive two-stage designs based on conditional power arguments utilizing the variability observed at the first stage. Fisher's product test for the p-values from the disjoint samples at the two stages is considered in detail for the comparison of the means of two normal populations. We show that stopping rules allowing for the early acceptance of the null hypothesis that are optimal with respect to the average sample size may lead to a severe decrease of the overall power if the sample size is a priori underestimated. This problem can be overcome by choosing designs with low probabilities of early acceptance or by midtrial adaptations of the early acceptance boundary using the variability observed in the first stage. This modified procedure is negligibly anticonservative and preserves the power. 相似文献
8.
Michael A. Proschan 《Biometrical journal. Biometrische Zeitschrift》2009,51(2):348-357
Adaptive clinical trials are becoming very popular because of their flexibility in allowing mid‐stream changes of sample size, endpoints, populations, etc. At the same time, they have been regarded with mistrust because they can produce bizarre results in very extreme settings. Understanding the advantages and disadvantages of these rapidly developing methods is a must. This paper reviews flexible methods for sample size re‐estimation when the outcome is continuous. 相似文献
9.
10.
Miller F 《Biometrical journal. Biometrische Zeitschrift》2010,52(5):577-589
We consider an adaptive dose‐finding study with two stages. The doses for the second stage will be chosen based on the first stage results. Instead of considering pairwise comparisons with placebo, we apply one test to show an upward trend across doses. This is a possibility according to the ICH‐guideline for dose‐finding studies (ICH‐E4). In this article, we are interested in trend tests based on a single contrast or on the maximum of multiple contrasts. We are interested in flexibly choosing the Stage 2 doses including the possibility to add doses. If certain requirements for the interim decision rules are fulfilled, the final trend test that ignores the adaptive nature of the trial (naïve test) can control the type I error. However, for the more common case that these requirements are not fulfilled, we need to take the adaptivity into account and discuss a method for type I error control. We apply the general conditional error approach to adaptive dose‐finding and discuss special issues appearing in this application. We call the test based on this approach Adaptive Multiple Contrast Test. For an example, we illustrate the theory discussed before and compare the performance of several tests for the adaptive design in a simulation study. 相似文献
11.
Martin Posch Nina Timmesfeld Franz Knig Hans‐Helge Müller 《Biometrical journal. Biometrische Zeitschrift》2004,46(4):389-403
For clinical trials with interim analyses conditional rejection probabilities play an important role when stochastic curtailment or design adaptations are performed. The conditional rejection probability gives the conditional probability to finally reject the null hypothesis given the interim data. It is computed either under the null or the alternative hypothesis. We investigate the properties of the conditional rejection probability for the one sided, one sample t‐test and show that it can be non monotone in the interim mean of the data and non monotone in the non‐centrality parameter for the alternative. We give several proposals how to implement design adaptations (that are based on the conditional rejection probability) for the t‐test and give a numerical example. Additionally, the conditional rejection probability given the interim t‐statistic is investigated. It does not depend on the unknown σ and can be used in stochastic curtailment procedures. (© 2004 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim) 相似文献
12.
Meinhard Kieser Brit Schneider Tim Friede 《Biometrical journal. Biometrische Zeitschrift》2002,44(5):641-652
Adaptive two‐stage designs allow a data‐driven change of design characteristics during the ongoing trial. One of the available options is an adaptive choice of the test statistic for the second stage of the trial based on the results of the interim analysis. Since there is often only a vague knowledge of the distribution shape of the primary endpoint in the planning phase of a study, a change of the test statistic may then be considered if the data indicate that the assumptions underlying the initial choice of the test are not correct. Collings and Hamilton proposed a bootstrap method for the estimation of the power of the two‐sample Wilcoxon test for shift alternatives. We use this approach for the selection of the test statistic. By means of a simulation study, we show that the gain in terms of power may be considerable when the initial assumption about the underlying distribution was wrong, whereas the loss is relatively small when in the first instance the optimal test statistic was chosen. The results also hold true for comparison with a one‐stage design. Application of the method is illustrated by a clinical trial example. 相似文献
13.
C. H. Ho 《Biometrical journal. Biometrische Zeitschrift》1991,33(6):735-740
Interim analysis in clinical trials involving two treatments are commonplace nowadays. Concerns from different points of view are widely seen in the literature. With a Bayesian approach there is no consideration of type I error and no power calculation. In contrast, there is no difficulty or arbitrariness in picking a prior distribution with a classical approach. In this paper, however, a stopping rule based on the Bayesian approach is discussed from a classical point of view. In specific, we consider application to normal sampling analyzed in stages and demonstrate the role of the prior distributions. In the first part of the paper, we define the stopping rules based on the posterior probabilities. We then develop the stopping boundaries in explicit forms, which can be easily computed with a hand calculator and a standard normal probability distribution table. We also summarize the frequency characteristics of this stopping rule into several results. The major question that is addressed in the second part of the paper is: how will a prior affect the results of a clinical trial study based on the posterior probabilities? The criteria for assessment will be strictly of a Neyman-Pearson kind. We use N(v, τ2) as the prior distribution for the difference between treatments, δ. We show that the test is unbiased if v = 0 or τ = ∞. In addition, some rather obvious facts are again summarized into a couple of results. We also discuss, with a table and a figure, the power functions of non-trivial cases with extreme v and τ using a numerical example. 相似文献
14.
Estimation following sequential tests 总被引：1，自引：0，他引：1
15.
Group sequential stopping rules are often used during the conduct of clinical trials in order to attain more ethical treatment of patients and to better address efficiency concerns. Because the use of such stopping rules materially affects the frequentist operating characteristics of the hypothesis test, it is necessary to choose an appropriate stopping rule during the planning of the study. It is often the case, however, that the number and timing of interim analyses are not precisely known at the time of trial design, and thus the implementation of a particular stopping rule must allow for flexible determination of the schedule of interim analyses. In this article, we consider the use of constrained stopping boundaries in the implementation of stopping rules. We compare this approach when used on various scales for the test statistic. When implemented on the scale of boundary crossing probabilities, this approach is identical to the error spending function approach of Lan and DeMets (1983). 相似文献
16.
17.
S. Huda 《Biometrical journal. Biometrische Zeitschrift》1989,31(7):827-832
Minimization of the variance of the difference between estimated responses at two points maximized over pairs of points in the region of interest is taken as the design criterion. Optimal third-order designs are derived for spherical co-centric regions of experimentation and interest with some restrictions imposed on the pairs of points under consideration. 相似文献
18.
Peter K. Kimani Susan Todd Nigel Stallard 《Biometrical journal. Biometrische Zeitschrift》2014,56(1):107-128
Recently, in order to accelerate drug development, trials that use adaptive seamless designs such as phase II/III clinical trials have been proposed. Phase II/III clinical trials combine traditional phases II and III into a single trial that is conducted in two stages. Using stage 1 data, an interim analysis is performed to answer phase II objectives and after collection of stage 2 data, a final confirmatory analysis is performed to answer phase III objectives. In this paper we consider phase II/III clinical trials in which, at stage 1, several experimental treatments are compared to a control and the apparently most effective experimental treatment is selected to continue to stage 2. Although these trials are attractive because the confirmatory analysis includes phase II data from stage 1, the inference methods used for trials that compare a single experimental treatment to a control and do not have an interim analysis are no longer appropriate. Several methods for analysing phase II/III clinical trials have been developed. These methods are recent and so there is little literature on extensive comparisons of their characteristics. In this paper we review and compare the various methods available for constructing confidence intervals after phase II/III clinical trials. 相似文献
19.
Traditionally drug development is generally divided into three phases which have different aims and objectives. Recently so-called adaptive seamless designs that allow combination of the objectives of different development phases into a single trial have gained much interest. Adaptive trials combining treatment selection typical for Phase II and confirmation of efficacy as in Phase III are referred to as adaptive seamless Phase II/III designs and are considered in this paper. We compared four methods for adaptive treatment selection, namely the classical Dunnett test, an adaptive version of the Dunnett test based on the conditional error approach, the combination test approach, and an approach within the classical group-sequential framework. The latter two approaches have only recently been published. In a simulation study we found that no one method dominates the others in terms of power apart from the adaptive Dunnett test that dominates the classical Dunnett by construction. Furthermore, scenarios under which one approach outperforms others are described. 相似文献
20.
C.-H. Ho 《Biometrical journal. Biometrische Zeitschrift》1991,33(7):817-827
Clinical trials research is mainly conducted for the purpose of evaluating the relative efficacy of two or more treatments. However, a positive response due to treatment is not sufficient to put forward a new product because one must also demonstrate safety. In such cases, clinical trials which show a positive effect would need to accrue enough patients to also demonstrate that the new treatment is safe. It is our purpose to show how the efficacy and safety problems can be combined to yield a more practical clinical trial design. In this paper we propose an asymmetric stopping rule which allows the experimenter to terminate a clinical trial early for a sufficiently negative result and to continue to a specified number of patients otherwise. As it turns out, a few interim tests will have negligible effects on the overall significance level. 相似文献